Table 2.
Study | Country | Patients testeda for KRASm (N) | Study type | Patients with the KRAS G12C mutation (n) |
KRAS G12C mutation prevalence within testeda population, % (n/N) |
Median KRAS G12C prevalence, % (n/N) | Patients with KRASm (N1) | KRAS G12C mutation prevalence within KRASm % (n/N1) | Median KRAS G12C prevalence/region % (n/N1) | KRASm prevalence % (N1/N) | Median KRASm prevalence/region KRASm % (N1/N) |
---|---|---|---|---|---|---|---|---|---|---|---|
European Union | |||||||||||
Gvaldin et al (2019)23 | Russia | 744 | Obs/NR | 19 | 2.6 | 3.5 (2.6-5.0) |
238 | 8.0 | 8.9 (8.0-14.0) |
32.0 | 36.5 (32.0-39.7) |
Palomba et al (2016)24 | Italy | 1284 | Obs/retrospective | 64 | 5 | 457 | 14.0 | 35.6 | |||
Malapelle et al (2012)25 | Italy | 1691 | Obs/retrospective | 64 | 3.8 | 671 | 9.5 | 39.7 | |||
Marchetti et al (2011)26 | Italy | 2519 | Obs/prospective | 78 | 3.1 | 940 | 8.3 | 37.3 | |||
Intercontinental region | |||||||||||
Gil Ferreira at. (2014)27 | Brazil | 7797 | Obs/retrospective | 206 | 2.6 | 2.6 | 2623 | 7.9 | 7.9 | 33.6 | 33.6 |
Japan and Asia-Pacific region | |||||||||||
Price et al (2020)28 | Australia | 1605 | Obs/retrospective | 63 | 3.9 | 2.5 (1.5 to 4.3) |
658 | 9.6 | 5.9 (3.6 to 9.6) |
41.0 | 42.1 (35.9 to 51.5) |
Wong et al (2020)29 | Australia | 1308 | Obs/prospective | 56 | 4.3 | 674 | 8.3 | 51.5 | |||
Li et al (2019b)30 | China | 526 | Obs/retrospective | 9 | 1.7 | 253 | 3.6 | 48.1 | |||
Li et al (2019a)31 | China | 1164 | Obs/retrospective | 29 | 2.5 | 490 | 5.9 | 42.1 | |||
Loong et al (2020)32 | China | 1114 | Obs/retrospective | 28 | 2.5 | 545 | 5.1 | 48.9 | |||
Luo et al 202033. | China | 655 | Obs/retrospective | 13 | 2.0 | 305 | 4.3 | 46.6 | |||
Shen et al, 201334 | China | 674 | Obs/retrospective | 10 | 1.5 | 242 | 4.1 | 35.9 | |||
Fu et al, 201935 | China | 5495 | Obs/retrospective | 127 | 2.3 | 2070 | 6.1 | 37.7 | |||
Won et al, 201736 | South Korea | 1092 | Obs/retrospective | 31 | 2.8 | 401 | 7.7 | 36.7 | |||
North America | |||||||||||
Nash et al (2010)37 | USA | 531 | Obs/retrospective | 15 | 2.8 | 4.1 (2.8 to 4.2) |
190 | 7.9 | 10.0 (7.9 to 10.4) |
35.8 | 39.0 (35.8 to 39.7) |
Paulino A (2014)38 | US | 577 | Obs/retrospective | 23 | 4.0 | 229 | 10 | 39.7 | |||
Maus et al (2014)39 | US | 838 | Obs/retrospective | 34 | 4.1 | 327 | 10.4 | 39.0 | |||
Nusrat et al (202040 | US | 3469 | Obs/retrospective | 146 | 4.2 | NR | NR | NR | |||
Greater than 1 geographical region | |||||||||||
Smith et al (2013b)41 | > 1 | 599 | Obs/retrospective | 17 | 2.8 | 2.8 | 258 | 6.6 | 6.6 | 43.1 | 43.1 |
aPatients with an evaluable test result.
Abbreviations: KRAS, Kirsten rat sarcoma virus gene; KRASm, KRAS mutation(s); KRAS G12C, KRAS with mutation at codon 12 that results in the substitution of glycine with cysteine; NR, not reported; Obs, observational; UK, United Kingdom; US, United States of America.